2 completed, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Apogenix GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease Asunercept, Placebo - COVID-19 | Phase 3 | Terminated | Apogenix GmbH | 34 | 2022-11-03 | 2023-08-29 |
| APG101 in Myelodysplastic Syndrome Treatment with APG101, Bone marrow collection, Blood drawings - Myelodysplastic Syndrome | Phase 1 | Completed | Apogenix GmbH | 20 | 2013-01-01 | 2016-08-24 |
| APG101 in Glioblastoma APG101, Blood drawing - Glioblastoma Multiforme | Phase 2 | Completed | Apogenix GmbH | 84 | 2009-12-01 | 2015-06-16 |
Anemia (1) · COVID-19 (1) · Glioblastoma (1) · Myelodysplastic Syndromes (1)
APG101 (2) · Blood Specimen Collection (1) · Recombinant Fusion Proteins (1) · Therapeutics (1)
Germany (3) · Austria (2) · France (1) · Georgia (1) · India (1) · Italy (1) · Poland (1) · South Africa (1) · Spain (1)
Eike C. Buss, MD (1) · Florian Nolte, MD (1) · Wolfgang Wick, MD (1)